{"filing":{"accession_number":"0001213900-26-077542","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"ea0297831-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026077542/ea0297831-6k_clearmind.htm"},"events":[{"id":17579,"run_id":15746,"accession_number":"0001213900-26-077542","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release discloses positive early insights from an ongoing Phase I/IIa first-in-human clinical trial (CMND-100) for alcohol use disorder, highlighting favorable safety profile, successful recruitment, and non-hallucinogenic differentiation. While the disclosure is operational in nature (clinical trial progress), it does not fit the specific event categories of earnings_release, exec_appointment/departure, or material_litigation. The material clinical trial progress and positive investigator feedback from leading institutions (Yale, Johns Hopkins) would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting materiality classification.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":[{"id":16106,"accession_number":"0001213900-26-077542","item_number":"EX-99.1","item_title":"ea029783101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses positive early insights from an ongoing Phase I/IIa first-in-human clinical trial (CMND-100) for alcohol use disorder, highlighting favorable safety profile, successful recruitment, and non-hallucinogenic differentiation. While the disclosure is operational in nature (clinical trial progress), it does not fit the specific event categories of earnings_release, exec_appointment/departure, or material_litigation. The material clinical trial progress and positive investigator feedback from leading institutions (Yale, Johns Hopkins) would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting materiality classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:01:42.628820+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16106,"accession_number":"0001213900-26-077542","item_number":"EX-99.1","item_title":"ea029783101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses positive early insights from an ongoing Phase I/IIa first-in-human clinical trial (CMND-100) for alcohol use disorder, highlighting favorable safety profile, successful recruitment, and non-hallucinogenic differentiation. While the disclosure is operational in nature (clinical trial progress), it does not fit the specific event categories of earnings_release, exec_appointment/departure, or material_litigation. The material clinical trial progress and positive investigator feedback from leading institutions (Yale, Johns Hopkins) would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting materiality classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:01:42.628820+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-07-13"}]}